[
    [
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药上半年净利润增长0.21%创近18年最低记录，核心产品纳入医保降价85%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "净利润",
                    "增长",
                    "医保降价"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药上半年净利润增长0.21%创近18年最低记录，核心产品纳入医保降价85%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "调整组织架构 恒瑞全面押注创新药 上半年研发投入同比增长近40%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "创新药",
                    "研发投入",
                    "增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "调整组织架构 恒瑞全面押注创新药 上半年研发投入同比增长近40%",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药净利微增0.2%，3个月涌入近25万散户，孙飘扬能否力挽狂澜？",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "净利",
                    "散户",
                    "孙飘扬"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药净利微增0.2%，3个月涌入近25万散户，孙飘扬能否力挽狂澜？",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药2021年上半年营收增长约18%，创新药贡献四成",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营收",
                    "创新药",
                    "增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药2021年上半年营收增长约18%，创新药贡献四成",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药艰难时刻：上半年净利润27亿增速创18年新低，半年市值蒸发2700亿 盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "净利润",
                    "增速",
                    "市值蒸发"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒瑞医药艰难时刻：上半年净利润27亿增速创18年新低，半年市值蒸发2700亿 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "胰岛素国采有望9月启动：外企份额或受冲击，国产渗透率提高",
            "features": {
                "keywords": [
                    "胰岛素",
                    "国采",
                    "外企",
                    "国产渗透率"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "胰岛素国采有望9月启动：外企份额或受冲击，国产渗透率提高",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药半年报：研发投入再创新高，创新药贡献四成营收",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "半年报",
                    "研发投入",
                    "创新药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药半年报：研发投入再创新高，创新药贡献四成营收",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药发布半年报，研发投入26亿，240多个临床在研",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "半年报",
                    "研发投入",
                    "临床在研"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药发布半年报，研发投入26亿，240多个临床在研",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药半年业绩出炉，营收133亿，创新药占四成，海外临床屡获进展",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "半年业绩",
                    "营收",
                    "创新药",
                    "海外临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药半年业绩出炉，营收133亿，创新药占四成，海外临床屡获进展",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-19",
            "original_text": "恒瑞医药上半年实现营收近133亿元，同比增17.58%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营收",
                    "增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药上半年实现营收近133亿元，同比增17.58%",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]